Drug Allergy Companies
Companies involved in addressing drug allergies typically contribute to the development of diagnostic tools, treatment options, and research in the field of allergic reactions to medications.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Drug Allergy Companies Update
-
May 2023: In collaboration with Genomics England, the Medicines and Healthcare Products Regulatory Agency (MHRA) will pilot a brand-new genetic research resource called a "biobank" in order to gain a better understanding of how the genetic composition of a patient can affect the safety of their medications. In addition to the MHRA's Yellow Card reporting site, the Yellow Card biobank will house patient samples and genetic information pertaining to adverse events and suspected side effects of pharmaceuticals and medical devices. As an integral component of a comprehensive strategy towards personalized medicine, this initiative entails the utilization of the biobank's repository of genetic data by researchers to ascertain the causative factor of a medication-induced adverse effect on a particular genetic characteristic. Consequently, physicians will be empowered to tailor prescriptions to patients' genetic profiles via rapid screening tests, ensuring that individuals throughout the United Kingdom receive the safest medication possible.
-
August 2022: Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd., an innovation-driven global pharmaceutical company, and Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, announced in August 2022 the launch of RYALTRISâ„¢ (olopatadine hydrochloride and mometasone furoate nasal spray) in the United States. The US Food and Drug Administration has approved RYALTRISâ„¢ for the treatment of seasonal allergic rhinitis (SAR) symptoms in pediatric and adult patients 12 years and older. This launch furthers Hikma's goal of expanding its specialty business in the United States by capitalizing on its leadership position as one of the largest providers of nasally administered medications used to treat seasonal allergies in the United States.
List of Drug Allergy Key companies in the market
- Bayer (US)
- HAL Allergy Group (the Netherlands)
- AstraZeneca (UK)
- MAGNA Pharmaceuticals, Inc. (US)
- Circassia (US)
- Stallergenes Greer (UK)
- Johnson & Johnson Services, Inc. (US)
Drug Allergy Market Highlights:
Drug Allergy Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
